Clinical Evaluation of Two Marketed Artificial Tears in Non-contact Lens Wearing Patients

Visual Acuity Clinical Trial

Official title:

Clinical Evaluation of Two Marketed Artificial Tears in Non-contact Lens Wearing Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03466086
• Other study ID #: CR-6013
• Status: Completed
• Phase: Phase 4
• Start date: February 9, 2018
• Est. completion date: May 16, 2018

Study information

• Verified date: June 2019
• Source: Johnson & Johnson Vision Care, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical study is a randomized, double-masked, cross-over, bilateral, 2 treatment x 2 period, dispensing 4-visit study with a 7-9 day washout period in between visits 2 and 3. The study will last approximately 3 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 57
• Est. completion date: May 16, 2018
• Est. primary completion date: May 16, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 69 Years

Eligibility

Inclusion Criteria:

• Potential subjects must satisfy all the following criteria to be enrolled in the study:

1. Subjects must be at least 18 years of age and no more than 69 years of age (inclusive)

2. Subjects must be non-contact lens wearers

3. Subjects must have a DEQ-5 score of >6 at either Visit 0 (pre-screen) and/or Visit 1 (screening).

4. Subjects must achieve visual acuity of 20/30 (equivalent to 0.18 logMAR) or better in each eye, either unaided or best corrected.

5. Subjects must possess a functional/usable pair of spectacles and bring them to every visit (only if applicable - to the investigators discretion).

6. Subjects must read, understand, and sign the Statement of Informed Consent.

7. Subjects must appear able and willing to adhere to the instructions set forth in this clinical protocol

Exclusion Criteria:

• Potential subjects who meet any of the following criteria will be excluded from participating in the study:

1. Currently pregnant or breast-feeding.

2. Diabetes.

3. Any ocular or systemic allergies or disease which may interfere with the clinical trial (at the investigator's discretion).

4. Any systemic disease, autoimmune disease, or use of medication which may interfere with the clinical trial (at the investigator's discretion).

5. Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV), by self-report

6. Any Grade 3 or greater biomicroscopy findings (this includes, corneal edema, corneal staining, corneal vascularization, conjunctival injection, tarsal abnormalities, bulbar injection) on the FDA scale

7. Any active ocular abnormalities/conditions that may interfere with the clinical trial (this includes, but not limited to, chalazia, recurrent styles, pterygium, infection, etc)

8. Any corneal distortion due to previous rigid gas permeable lens wear, surgery or pathology

9. History of any ocular or corneal surgery (e.g. RK, PRK, LASIK)

10. Participation in any pharmaceutical or medical device related clinical trial within 14 days prior to study enrollment.

11. History of binocular vision abnormality or strabismus.

12. Habitual wearers of soft contact lenses in the past 1 month or rigid gas permeable lens within the past 3 months

13. Current habitual use of Prescription Only Medicines (POM) to treat dry eye or ocular discomfort, ocular steroids, or any medication (RX or OTC) that would interfere with the clinical study (at the discretion of the investigator).)

14. Employees of investigational clinic (investigator, coordinator, and technician etc) or family member of an employee of the clinical site by self-report.

In addition to the above criteria, patients with any allergy or sensitivity to ingredients that this product may contain (liposomes, sodium hyaluronate, vitamin E polyethylene glycol succinate (TPGS), polyethylene glycol 400 (PEG 400), disodium edetate, polyhexanide methylbiguanide, propylene glycol, boric acid, dimyristoyl phosphatidylglycerol, edetate disodium, hydroxypropyl guar, mineral oil, polyoxyl 40 sterate, polyquaternium-1, sorbitan tristearate, sorbitol, hydrochloric acid and/or sodium hydroxide) should not participate in the study.

Related Conditions & MeSH terms

• Visual Acuity

Intervention

Device:
• Test Eye Drops
blink® intensive TRIPLE ACTION 3 in 1 eye drops
• Control Eye Drops
Systane® BALANCE eye drops

Locations

Country	Name	City	State
United Kingdom	The University of Manchester	Manchester

Sponsors (1)

Lead Sponsor	Collaborator
Johnson & Johnson Vision Care, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ocular Comfort	Ocular comfort was measured using the visual analogue scale of 0 to 100. Where 0 is extremely uncomfortable and 100 is extremely comfortable.	1-Week Follow-up
Secondary	Subjective Dryness Rating	Subjective dryness was assessed using Ocular Surface Disease Index (OSDI©) instrument. Dryness is evaluated on a scale of 0 to 100, where higher scores indicate more symptoms of dryness	1-Week Follow-up